UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019-07, Vol.22 (4), p.817-827

2019

Volltextzugriff (PDF)

A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study

International journal of clinical oncology, 2021-05, Vol.26 (5), p.941-950

2021

Volltextzugriff (PDF)

Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer

Scientific reports, 2023-11, Vol.13 (1), p.19399-19399, Article 19399

2023

Volltextzugriff (PDF)

C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel

Scientific reports, 2023-05, Vol.13 (1), p.8815-8815, Article 8815

2023

Volltextzugriff (PDF)

Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel

Scientific reports, 2024-03, Vol.14 (1), p.5311-5311, Article 5311

2024

Volltextzugriff (PDF)

Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)

BMC cancer, 2022-01, Vol.22 (1), p.19-19, Article 19

2022

Volltextzugriff (PDF)

A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site

Japanese journal of clinical oncology, 2022-12, Vol.52 (12), p.1416-1422

2022

Volltextzugriff (PDF)

Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer

Cancer science, 2019-03, Vol.110 (3), p.1032-1043

2019

Volltextzugriff (PDF)

Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer

Cancer science, 2019-11, Vol.110 (11), p.3565-3572

2019

Volltextzugriff (PDF)

Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non‐squamous, non‐small cell lung cancer: TORG (thoracic oncology research group) 1321

Cancer medicine (Malden, MA), 2023-07, Vol.12 (14), p.14988-14999

2023

Volltextzugriff (PDF)

Correction to: A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study

International journal of clinical oncology, 2021-05, Vol.26 (5), p.951-953

2021

Volltextzugriff (PDF)

First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2018-09, Vol.21 (5), p.792-801

2018

Volltextzugriff (PDF)

Body effect on SAR in the human eye close to metallic spectacles for plane-microwave exposure

IEICE COMMUNICATIONS EXPRESS, 2017, Vol.6 (10), p.602-606

2017

Volltextzugriff (PDF)

Extramedullary Plasmacytoma as an Uncommon Cause of Gastrorrhagia

Internal Medicine, 2010, Vol.49(15), pp.1679-1680

2010

Volltextzugriff (PDF)

Vesicocutaneous fistula formation during treatment with sunitinib malate: Case report

BMC gastroenterology, 2010-11, Vol.10 (1), p.128-128, Article 128

2010

Volltextzugriff (PDF)

Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 Plus Bevacizumab

Japanese Clinical Medicine, 2014-01, Vol.2014 (5), p.19-23

2014

Volltextzugriff (PDF)

Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer

Future oncology (London, England), 2023-07, Vol.19 (23), p.1593-1600

2023

Volltextzugriff (PDF)

Transfer of Antigen-Pulsed Dendritic Cells Induces Specific T-Cell Proliferation and a Therapeutic Effect against Long-Term Helicobacter pylori Infection in Mice

Infection and Immunity, 2006-02, Vol.74 (2), p.984-993

2006

Volltextzugriff (PDF)

First-line FOLFOX therapy for advanced esophageal squamous cell carcinoma: Multicenter prospective study in Japan

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.280-280

2024

Volltextzugriff (PDF)

Precise Gate Timing Control based on State Trajectory Analysis for 3.3kW Bidirectional AC/DC Converter

2023 IEEE Applied Power Electronics Conference and Exposition (APEC), 2023, p.1997-2001

2023

Volltextzugriff (PDF)

VOYAGER (KSCC1902): A single-arm, multicenter, phase II study of early induction of nivolumab during second-line treatment with taxane ± ramucirumab for advanced gastric or gastro-esophageal junction cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4028-4028

2022

Volltextzugriff (PDF)

Comparison of Amoxicillin-Metronidazole Plus Famotidine or Lansoprazole for Amoxicillin-Clarithromycin-Proton Pump Inhibitor Treatment Failures for Helicobacter pylori Infection

Helicobacter (Cambridge, Mass.), 2006-10, Vol.11 (5), p.436-440

2006

Volltextzugriff (PDF)

1 – 25 von 236

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(192)
Mit Volltextzugriff
(190)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(114)
Life Sciences & Biomedicine
(82)
Humans
(49)
Animals
(41)
Mice
(34)
Male
(27)
Female
(26)
Oncology
(26)
Aged
(22)
Cell Biology
(19)
Mice, Inbred C57bl
(17)
Chemotherapy
(16)
Middle Aged
(16)
Medicine
(13)
Multidisciplinary Sciences
(13)
Science & Technology - Other Topics
(13)
Medicine & Public Health
(12)
Metastasis
(12)
Pancreatic Cancer
(12)
Patients
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial

A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study

Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer

C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel

Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel

Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)

A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site

Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel

Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer

A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer

Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer

Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum

Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non‐squamous, non‐small cell lung cancer: TORG (thoracic oncology research group) 1321

Correction to: A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study

First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study

Body effect on SAR in the human eye close to metallic spectacles for plane-microwave exposure

Extramedullary Plasmacytoma as an Uncommon Cause of Gastrorrhagia

Vesicocutaneous fistula formation during treatment with sunitinib malate: Case report

Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 Plus Bevacizumab

Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer

Transfer of Antigen-Pulsed Dendritic Cells Induces Specific T-Cell Proliferation and a Therapeutic Effect against Long-Term Helicobacter pylori Infection in Mice

First-line FOLFOX therapy for advanced esophageal squamous cell carcinoma: Multicenter prospective study in Japan

Precise Gate Timing Control based on State Trajectory Analysis for 3.3kW Bidirectional AC/DC Converter

VOYAGER (KSCC1902): A single-arm, multicenter, phase II study of early induction of nivolumab during second-line treatment with taxane ± ramucirumab for advanced gastric or gastro-esophageal junction cancer

Comparison of Amoxicillin-Metronidazole Plus Famotidine or Lansoprazole for Amoxicillin-Clarithromycin-Proton Pump Inhibitor Treatment Failures for Helicobacter pylori Infection

Suchergebnisse filtern